Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Tozasertib (VX-680, MK-0457) Chemical Structure

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

16 Customer Reviews

  • (G) Nocodazole-arrested HeLa cells were treated with VX-680 and MG132 and stained for CENP-E (Green), pT422 (Red) and DNA (Blue). (H) pT422 fluorescence intensity was normalized to the total CENP-E fluorescence. Plots show the mean of > 15 cells per condition from two independent experiments.

    Cell 2010 142, 444–455. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    Senescence induction upon PKCι depletion combined with aurora kinase inhibition. ( a) MCF7 cells were transfected as above to deplete PKCι . Two days after transfection, cells were treated for the indicated time period with 400 n M VX-680. Medium with VX-680 was then removed and fresh medium was added. Cells were stained for SA-b -gal activity 5 days after the start of transfection.* indicates a P value <0.05. ( b) MCF7 cells were treated as above. Five days after transfection, cells were fixed and assessed for the presence of gH2AX foci by immunofluorescence microscopy. (c, d) MCF7 cells were treated with dimethyl sulfoxide (DMSO) control or 400 n M VX-680 for the indicated time periods. Total cell lysates were then analyzed by western blotting for levels of p21 and GAPDH (as loading control). A representative blot is shown in panel c. Quantitation of changes in p21 levels (normalized to vehicle-treated controls) is shown in panel d. The data shown are the means ±s.e. of three independent experiments.

    Oncogene 2012 31, 3584-96. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • Senescence induction upon PKCι depletion combined with aurora kinase inhibition in glioblastoma cells. (a, b) U87MG cells were transfected as above to deplete PKCι. Two days after transfection, cells were treated for 72 ( a)or24h (b) with 400 nM VX-680. Medium with VX-680 was then removed and fresh medium was added. Cells were stained for SA-b-gal activity 5 days after the start of transfection. * indicates a P value <0.05. (c) U87MG cells were treated as described in panel a above. Five days after transfection, cells were fixed and assessed for the presence of gH2AX foci by immunofluorescence microscopy. (d) U87MG cells were treated with the dimethyl sulfoxide (DMSO) control or 400 n M VX-680 for the indicated time periods. Total cell lysates were then analyzed by western blotting for levels of p21. The bar graph shows quantitation of p21 levels (normalized to vehicle-treated controls) from three independent experiments. A representative blot is also shown, with lanes aligned to correspond to the labels on the graph.

    Oncogene 2012 31, 3584-96. Tozasertib (VX-680, MK-0457) purchased from Selleck.

     

    Aurora-A inhibitors severely impair neuronal migration. Migration of granular neurons after treatment of Aurora-A inhibitors was examined. a, Western blotting analysis of proteins or phosphorylated proteins. Aurora-A and NDEL1 displayed similar expression levels, whereas phosphorylated Aurora-A and NDEL1 proteins were decreased during treatment with Aurora-A inhibitors. Relative intensities of the bands of Western blotting are displayed at the bottom.

    J Neurosci 2012 32, 11050-11066. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • B, BLQ1 and UCSF02 cells were treated with increasing concentrations of VX-680 for 48 hours. The percentage of apoptotic cells was determined by fluorescence-activated cell sorting analysis. C, BLQ1 cells were treated with 1 μmol/L VX-680 and cell cycle distribution was determined by flow cytometry at time points of 24 and 48 hours.

    Mol Cancer Ther 2010 9, 1318–1327. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    VX-680 eliminates Bcr/Abl kinase activities. BLQ1 (T315I mutation) and TXL2 (no mutation) cells were treated with the indicated concentrations of VX-680 with or without 100 nmol/L dasatinib for 24 hours. Western blot analysis was done on total lysates with the antibodies indicated to the left. Blots were stripped and reprobed with Bcr (N-20), Src, and GAPDH antibodies as loading controls.

    Mol Cancer Ther 2010 9, 1318–1327. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • Responses of human ALL cells to short-term VX-680 treatment. A, BLQ1 cells were treated with 1 μmol/L VX-680 for 3 days. After 3 days, the drug was removed from the medium and cells were cultured without VX-680. During this period (days 3-21) without drug, viability (top left), cell numbers (bottom left), and cell cycle distribution (right) of BLQ1 cells were assessed. B, BLQ1 and BLQ1-VX-Tx cells were cytospun onto glass slides and fixed, dried, and stained with Wright-Giemsa on day 21. All images are at ×63 magnification. C, BLQ1 and BLQ1-VX-Tx cells were treated with 1.5 μmol/L VX-680 or 5 nmol/L vincristine for 72 hours. Cell viability was measured by trypan blue exclusion. *, P < 0.05, vincristine-treated BLQ1 compared with vincristine-treated BLQ1-VX-Tx.

    Mol Cancer Ther 2010 9, 1318–1327. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    VX-680 and dasatinib synergize to induce cytotoxic activity in wild-type Bcr/Abl-positive human ALL cells. A, TXL2 and UCSF02 cells were exposed to 1 μmol/L VX-680 with or without 100 nmol/L dasatinib for 24 to 72 hours as indicated, after which the percentage of viable cells was determined by trypan blue exclusion. B, TXL2 cells were treated with or without VX-680 and dasatinib for 48 hours in triplicate. **, P < 0.001, VX-680 and dasatinib cotreated TXL2 compared with VX-680-treated or dasatinib alone-treated TXL2 cells. Apoptotic cells were defined by flow cytometry as Annexin V and propidium iodide (PI) double-positive cells. C, TXL2 cells were exposed to VX-680 and/or dasatinib and cell cycle distribution was assessed by flow cytometry.

    Mol Cancer Ther 2010 9, 1318–1327. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • MTT assay reveals a dose-dependent decrease in cell viability in mouse derived brainstem glioma cells treated with VX-680 ( P < 0.001) after 72 h of treatment. The error bars represent the standard deviation. Propidium iodide based cell sorting of mouse derived brainstem glioma cells after 72 h treatment with 5 μM reversine or 100 nM VX-680 respectively reveals increased cell populations with 4N and 8N DNA content as compared to vehicle control.

    Brain Pathol 2012 23, 244-53. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    Treatment of mouse derived brainstem glioma cells for 72 h with 5 μM reversine or 100 nM VX-680 increases cell size compared with vehicle-treated control and leads to irregular-shaped nuclei and micronuclei (F–H). Images F–H represent immunofluorescent staining for GFAP (green) with DAPI counter-stain (blue) and were taken at 400 ×magnification.

    Brain Pathol 2012 23, 244-53. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • C, E: Expression of Aur-A and phosphorylated histone H3 in TPC-1 cells after VX-680 treatment. D, F: Expression of phosphorylated histone H3 in PTC tumor tissues after VX-680 treatment.

    Biochem Biophys Res Commun, 2016, 473(1):212-8. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    Apoptosis induction in HB cells treated with a combination of VX-680. HUH6 (a) and HepT1 ( b ) were incubated with VX-680 (6 and 12.5 μM). Caspase-3 activation was detected with the NucView- 488 substrate 24 h later. Green fluorescent cells denote apoptotic cells.Scale bar represents 50 μm.

    Pediatr Surg Int 2012 28, 579-89. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    ENMD-2076 has benn tested it on two different neurobiastoma cell lines(SK-N-BE(2) and CHP-134),being calculated the IC50 by a WST-1(Roche) proliferation assay, as shown in the table below. Its in vitro activity is in the micromolar range and has a comparable effect on both lines.VX-680 was used as standard, and it proved more potent on CHP-134 cells.

    Dr. Antonino Maria Sparta ,University of Trento. Tozasertib (VX-680, MK-0457) purchased from Selleck.

  • SDS-PAGE of CHP-134 cells extracts after 24 h exposure to the indicated drug and concentration. N-myc levels were evaluated and compared to beta actin used as house-keeping protein. Aurora A blockade seems to diminish N-myc expression or stability.

    Dr. Antonino Maria Sparta ,University of Trento. Tozasertib (VX-680, MK-0457) purchased from Selleck.

    Western blot analysis of Histone and Aurora kinase. 0-10μM MK0457 was added.

    Dr. Zhang of Tianjin Medical University. Tozasertib (VX-680, MK-0457) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Targets
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMECzN|gh|ryP MYnTRW5IWkWU
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonqTWM2OD1yLkCwOFA1KM7:TR?= M4DQNnNCVkeURWK=
MFH-ino NHLZTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEC5PUDPxE1? NWjhcZRFW0GQR2LFVi=>
NTERA-S-cl-D1 M{\xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjlTGxoUUN3ME2wMlAyPDN2IN88US=> MnfjV2FPT1KHUh?=
697 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTlTHVQUUN3ME2wMlAzPDdzIN88US=> NHrhU|lUSU6JUlXS
NALM-6 NYq5Oo9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEK1OVIh|ryP MWPTRW5IWkWU
ES8 M3jBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnkWWVWUUN3ME2wMlA1PjF|IN88US=> M3zBZ3NCVkeURWK=
HUTU-80 NGLGPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEWyPVkh|ryP Ml3lV2FPT1KHUh?=
MV-4-11 M4nufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEe3PFIh|ryP MmLZV2FPT1KHUh?=
MONO-MAC-6 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrXR|RtUUN3ME2wMlA4QDd7IN88US=> M1HlVnNCVkeURWK=
LC-2-ad NHX4WmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDSOpNFUUN3ME2wMlA5Pzh7IN88US=> MXjTRW5IWkWU
BL-41 M3fn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX2TWM2OD1yLkGwOFQ2KM7:TR?= MVTTRW5IWkWU
A4-Fuk NGDCNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:4T2tTUUN3ME2wMlEyPTZ|IN88US=> MV;TRW5IWkWU
SW954 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMUKyNlkh|ryP MU\TRW5IWkWU
BV-173 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfTXlNFUUN3ME2wMlEzPjRzIN88US=> NILVUZNUSU6JUlXS
TE-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMUS5PFIh|ryP MljIV2FPT1KHUh?=
SK-UT-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fLe2lEPTB;MD6xOVk3PSEQvF2= Mn\lV2FPT1KHUh?=
SIG-M5 NEn1d|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMU[3NFch|ryP NGnBPWdUSU6JUlXS
OCUB-M MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpO|g4UUN3ME2wMlE3QTh|IN88US=> NXPI[2VQW0GQR2LFVi=>
K052 NF3zemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnznTWM2OD1yLkG5OFgh|ryP MkXBV2FPT1KHUh?=
VA-ES-BJ MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIflVnZKSzVyPUCuNlAxQDZizszN NGn5bYtUSU6JUlXS
SW982 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3EW2lKSzVyPUCuNlE{QCEQvF2= NIXYWGRUSU6JUlXS
LB647-SCLC M3;FVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjYUWtKSzVyPUCuNlE2OjNizszN Mn:wV2FPT1KHUh?=
PSN1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXsdFJOUUN3ME2wMlIzODJ4IN88US=> NHrIPIZUSU6JUlXS
BB30-HNC NXG3O2E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMkK1PVEh|ryP M2HLc3NCVkeURWK=
ST486 NXn3eot3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\CVGlEPTB;MD6yN|A5PyEQvF2= MlHMV2FPT1KHUh?=
MOLT-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHmTWM2OD1yLkKzN|M4KM7:TR?= NEL1O4hUSU6JUlXS
EW-16 NHnnSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHs[m14UUN3ME2wMlI{PzZ6IN88US=> M4C2fnNCVkeURWK=
KS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDtTWM2OD1yLkKzO|g2KM7:TR?= M2r6[nNCVkeURWK=
SR M1fHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKy[5VSUUN3ME2wMlI1PTZ2IN88US=> MV3TRW5IWkWU
KM12 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnxRYlKSzVyPUCuNlY{PiEQvF2= M33KTHNCVkeURWK=
EM-2 M1La[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMk[2OFEh|ryP NWr6OYl5W0GQR2LFVi=>
MEG-01 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPiO2IzUUN3ME2wMlI4QDR7IN88US=> NWDxRoxHW0GQR2LFVi=>
NB13 NHzvPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nscmlEPTB;MD6yO|k5PCEQvF2= NYW3[G1EW0GQR2LFVi=>
RKO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\BTWM2OD1yLkOwPFE{KM7:TR?= NYSwXWF5W0GQR2LFVi=>
CESS M3TrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK1S49KSzVyPUCuN|E{OjhizszN NIXRbYpUSU6JUlXS
EoL-1-cell M4jFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPlXIZKSzVyPUCuN|M1PTlizszN NVXkSJpDW0GQR2LFVi=>
DOHH-2 M4XuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6fIdKSzVyPUCuN|M4QDFizszN NYPBeZE5W0GQR2LFVi=>
A388 NYrCdlBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;3boJKSzVyPUCuN|QxQDZizszN MoLrV2FPT1KHUh?=
LAMA-84 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnuTWM2OD1yLkO1NVc5KM7:TR?= NFTy[YdUSU6JUlXS
IMR-5 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSxTWM2OD1yLkO1OVQh|ryP MVrTRW5IWkWU
KARPAS-422 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nuUmlEPTB;MD6zO|I4OiEQvF2= NX7kbJc2W0GQR2LFVi=>
MRK-nu-1 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Ucm5JUUN3ME2wMlM5OTNizszN MljOV2FPT1KHUh?=
BL-70 M3nNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PJNmlEPTB;MD6zPFk4PCEQvF2= NH3HfmlUSU6JUlXS
LXF-289 NI\nW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEC0NFYh|ryP M1zjSXNCVkeURWK=
RL95-2 NH\GXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEC1Olch|ryP NFvtZXJUSU6JUlXS
QIMR-WIL M1TDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPZb5dKSzVyPUCuOFI3PzZizszN NFLQNJdUSU6JUlXS
K-562 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\EVXRKSzVyPUCuOFM1PzJizszN NXznPZZ4W0GQR2LFVi=>
NCI-H510A MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C0WmlEPTB;MD60N|gzOyEQvF2= MUjTRW5IWkWU
NCI-H524 NXL4fHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwNUGxOFch|ryP Mn7yV2FPT1KHUh?=
KE-37 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwNUKxNFIh|ryP MU\TRW5IWkWU
KP-N-YS M2Czemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nvV2lEPTB;MD61OFM6OiEQvF2= NX25RZI1W0GQR2LFVi=>
LS-411N NGf1SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzeWlEPTB;MD61O|c2OiEQvF2= MkD5V2FPT1KHUh?=
CTV-1 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXTVZKSzVyPUCuOVg4PzNizszN MX3TRW5IWkWU
NCI-SNU-16 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\TcWFKSzVyPUCuOlM2PzFizszN NGrGPZZUSU6JUlXS
HT-144 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT0TWM2OD1yLk[zO|k5KM7:TR?= MUfTRW5IWkWU
NCI-H187 NWj0S|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;wNlFKSzVyPUCuOlQyOyEQvF2= M1PJWHNCVkeURWK=
OCI-AML2 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwNkS0NFMh|ryP NE\vcWxUSU6JUlXS
CCRF-CEM NVP5T4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTSdIxwUUN3ME2wMlY2OzR4IN88US=> NGLoZXNUSU6JUlXS
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLaNnNPUUN3ME2wMlY3PDV6IN88US=> M2nsTHNCVkeURWK=
IST-SL2 NGjSfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwN{G5PFIh|ryP MXjTRW5IWkWU
NB6 NYLPWo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwN{eyOVQh|ryP NUHOZ4pQW0GQR2LFVi=>
SK-PN-DW NI\sOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT0UHdKSzVyPUCuO|kyPCEQvF2= M3\LXnNCVkeURWK=
HCC1599 NWjYPWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTUNYZKSzVyPUCuPFA5PzRizszN NGHNdnpUSU6JUlXS
MC116 M3TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X4b2lEPTB;MD64OVAyOSEQvF2= MkP4V2FPT1KHUh?=
TE-15 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPHTWM2OD1yLki1NFk5KM7:TR?= NV20ZXpIW0GQR2LFVi=>
HOP-62 M3;PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\wRXZKSzVyPUCuPFY{OjlizszN MoTUV2FPT1KHUh?=
TGBC24TKB MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGO5BKSzVyPUCuPFY{QDVizszN NWfwTI5OW0GQR2LFVi=>
HCE-4 M2PmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jKVWlEPTB;MD64PFA3OyEQvF2= NEHaU4lUSU6JUlXS
ALL-PO MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[3bGZKSzVyPUCuPFgyPzVizszN Mn[yV2FPT1KHUh?=
KGN NFy5eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfMdFVKSzVyPUCuPFk6QTVizszN Mnn0V2FPT1KHUh?=
ML-2 NXjKWnN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOUCyOVkh|ryP MmnsV2FPT1KHUh?=
ES4 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfMT41FUUN3ME2wMlkyOTJ6IN88US=> NVv6dGFkW0GQR2LFVi=>
SF126 M3fnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WzUGlEPTB;MD65OFgyQSEQvF2= MlnLV2FPT1KHUh?=
SK-N-DZ NYm2S4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTlVXM3UUN3ME2wMlk3OTh7IN88US=> MmTpV2FPT1KHUh?=
HCC1187 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDCTWM2OD1zLkCwOVA2KM7:TR?= NW\LZ2tRW0GQR2LFVi=>
DU-4475 M{jMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n6N2lEPTB;MT6wNVc2PiEQvF2= Mk\5V2FPT1KHUh?=
NKM-1 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwMEK3O|Uh|ryP MXvTRW5IWkWU
HL-60 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnrTWM2OD1zLkC2OVc1KM7:TR?= MWfTRW5IWkWU
SBC-1 M2Hpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnLUmVKSzVyPUGuNVI2PDJizszN NH71RYVUSU6JUlXS
TE-10 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK5bo5KSzVyPUGuNVI6PDZizszN MoDoV2FPT1KHUh?=
ETK-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCT5ZKSzVyPUGuNVM3OTNizszN M3TSVHNCVkeURWK=
HAL-01 NYnzdmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\1TWM2OD1zLkG2O|A6KM7:TR?= NF\5ZmxUSU6JUlXS
BB65-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:zTGdKSzVyPUGuNVgxODVizszN M4O4[XNCVkeURWK=
EW-1 NYT5TXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\3fVR{UUN3ME2xMlE5PTZ{IN88US=> NGPE[mZUSU6JUlXS
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfaUHdvUUN3ME2xMlIyOTFzIN88US=> NUPyRYNqW0GQR2LFVi=>
SK-LMS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n3bWlEPTB;MT6yNlIyOiEQvF2= M1P2OXNCVkeURWK=
DEL NITEVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzYOohvUUN3ME2xMlI2PjR|IN88US=> MVfTRW5IWkWU
GT3TKB MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TqV2lEPTB;MT6yPFA2PyEQvF2= Ml7ZV2FPT1KHUh?=
MOLT-16 NXHwTIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO0TWM2OD1zLkO1OFA2KM7:TR?= NHn6fIdUSU6JUlXS
CMK M{LxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzMUVZKSzVyPUGuOFIyOTdizszN NHfzU5VUSU6JUlXS
NB5 NWnKVYs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:2XXVYUUN3ME2xMlY1OjJ7IN88US=> M1S0THNCVkeURWK=
NCI-H1963 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPPfJVKSzVyPUGuO|A2QDNizszN M3v3c3NCVkeURWK=
KURAMOCHI MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwN{i5NVEh|ryP NWfLWpY4W0GQR2LFVi=>
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHUTWM2OD1zLkiwN|Y5KM7:TR?= MljXV2FPT1KHUh?=
NCI-H1304 NGTmRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjtTWM2OD1zLkizNFc{KM7:TR?= MoS2V2FPT1KHUh?=
A101D M{jkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexcJVKSzVyPUGuPFc{QTVizszN MnrIV2FPT1KHUh?=
SCLC-21H NETrUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLRTWM2OD1zLkm3NFU4KM7:TR?= M4rGcnNCVkeURWK=
GB-1 NHrwc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkeHc{UUN3ME2yMlAyPjR5IN88US=> NHrq[GFUSU6JUlXS
KARPAS-45 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT5eYJKSzVyPUKuNFI3PTRizszN MXnTRW5IWkWU
ATN-1 NEn5doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnqOYRuUUN3ME2yMlAzQDV6IN88US=> MWPTRW5IWkWU
NCI-H720 NFvOeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwME[yOFQh|ryP MoKyV2FPT1KHUh?=
RPMI-6666 NV3qRop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P5UWlEPTB;Mj6xOlIxPyEQvF2= MX\TRW5IWkWU
NB17 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwMkmyO{DPxE1? MXXTRW5IWkWU
IST-SL1 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[4R414UUN3ME2yMlI6PzZ3IN88US=> MXHTRW5IWkWU
SH-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n3bGlEPTB;Mj6zNlQ3QSEQvF2= M1X2[XNCVkeURWK=
K5 NYXjfpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmyRpFPUUN3ME2yMlQxOzF7IN88US=> MUTTRW5IWkWU
OVCAR-4 NYO2RVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrLUGQ2UUN3ME2yMlQ3OTNizszN NI\wZ4RUSU6JUlXS
ACN M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrsTWM2OD1{LkWwNlE{KM7:TR?= NFjQfGpUSU6JUlXS
TGW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX76XG5WUUN3ME2yMlY2QDN{IN88US=> Ml75V2FPT1KHUh?=
NCI-H2107 NV75PHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f3bmlEPTB;Mj64N|cyOSEQvF2= M{fvRXNCVkeURWK=
NCI-H82 NUjGVZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0PHZKSzVyPUKuPFM5OzhizszN M3vQbHNCVkeURWK=
SK-N-FI M2q4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny4TWM2OD1{Lki2PFY5KM7:TR?= NIPYcmFUSU6JUlXS
LB1047-RCC MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ZTWM2OD1{Lki4NVI3KM7:TR?= NEn2fldUSU6JUlXS
LU-134-A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjDTWM2OD1{Lki5NlYh|ryP Ml:zV2FPT1KHUh?=
NCI-H209 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfJU2tKSzVyPUKuPVEzPTNizszN NXzxOpJMW0GQR2LFVi=>
NOMO-1 M{nKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCeG9KSzVyPUOuNFIzPzRizszN M1vxfHNCVkeURWK=
RH-1 NFfQOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwMUeyPVEh|ryP NUjyNpY5W0GQR2LFVi=>
LOUCY M1G1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLhbFNvUUN3ME2zMlE5Pjl|IN88US=> MXTTRW5IWkWU
TE-9 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOUmlEPTB;Mz6yOlc{PiEQvF2= NYXuT5ZxW0GQR2LFVi=>
PF-382 M3K0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\NZWNzUUN3ME2zMlM2Pzd6IN88US=> MYnTRW5IWkWU
RPMI-8402 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrBTWM2OD1|LkW4OlA{KM7:TR?= NUHqWmJZW0GQR2LFVi=>
HEL M12yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHLTWM2OD1|Lk[zNkDPxE1? NU\2NFl2W0GQR2LFVi=>
NOS-1 NVfGOlA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\tc2NKSzVyPUOuPFQ4PTRizszN NV\rPZFpW0GQR2LFVi=>
ES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzR4N4UUN3ME2zMlkzOjl|IN88US=> NEXKcYxUSU6JUlXS
NCI-H2171 M{nuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HUO2lEPTB;Mz65NlQzOyEQvF2= M3XnVXNCVkeURWK=
NCI-H747 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLRd5pEUUN3ME2zMlk1OjJzIN88US=> NIq3NZJUSU6JUlXS
MHH-NB-11 NYLHS5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T1V2lEPTB;Mz65OVMyOiEQvF2= Mn;VV2FPT1KHUh?=
MZ1-PC M{DHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqyZmxxUUN3ME2zMlk6OjRizszN M3K1THNCVkeURWK=
MMAC-SF NUj5VnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwMEK0Olch|ryP MoDPV2FPT1KHUh?=
NMC-G1 M3TwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwMkK3NlMh|ryP M1HLO3NCVkeURWK=
SW872 NWHpT2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwM{SzOEDPxE1? NYPl[ndjW0GQR2LFVi=>
TE-12 NGTIdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnScXZNUUN3ME20MlU3Ozl2IN88US=> M37OZXNCVkeURWK=
LU-139 NGSw[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS3PWx1UUN3ME20MlYyQDN3IN88US=> NFnGTI1USU6JUlXS
HC-1 NVXIfXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPifXRNUUN3ME20MlY6PDl2IN88US=> NV\NbVBIW0GQR2LFVi=>
COR-L279 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrEUJZRUUN3ME20Mlc2QDlzIN88US=> NUPFNWN[W0GQR2LFVi=>
SF268 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHqW2VKSzVyPUSuO|k6OTZizszN NEC4V3FUSU6JUlXS
MC-CAR M1rTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTVwME[3OVch|ryP MYnTRW5IWkWU
TK10 NWnmVWZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljYTWM2OD13LkO1OFY6KM7:TR?= NYDQSnFiW0GQR2LFVi=>
TE-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrCTWM2OD13LkS5NFA1KM7:TR?= NGm5ZWpUSU6JUlXS
NCI-H2126 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\kW2lEPTB;NT62OFU4PCEQvF2= NIDE[YpUSU6JUlXS
Daudi MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXHT41KSzVyPUWuOlkyOiEQvF2= Mn3sV2FPT1KHUh?=
NCI-H1648 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULDNnVEUUN3ME21MlgyPDV2IN88US=> NVTsc|BsW0GQR2LFVi=>
OS-RC-2 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfsTWM2OD13Lkm4OVk4KM7:TR?= NESzRXJUSU6JUlXS
DJM-1 M{fNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHxTWM2OD14LkO0OlY3KM7:TR?= NI\GcYRUSU6JUlXS
LS-1034 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\6UGpKSzVyPU[uO|U3PiEQvF2= NEDFb|BUSU6JUlXS
NCI-H1581 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDJTWM2OD14Lke4OFA2KM7:TR?= MYfTRW5IWkWU
UACC-257 Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTdwMES1NVIh|ryP MWLTRW5IWkWU
KM-H2 NX71PItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknzTWM2OD15LkG4OFU4KM7:TR?= NFzqdXFUSU6JUlXS
NCI-H1436 NFTkNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHzTWM2OD15Lk[5PVMzKM7:TR?= NWq0bnV{W0GQR2LFVi=>
IA-LM MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSzTWM2OD15Lki1PUDPxE1? M{PCWnNCVkeURWK=
NCI-H526 NFrOUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTaO3FWUUN3ME24MlI2PjN5IN88US=> MVPTRW5IWkWU
GCIY M3PRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T3OmlEPTB;OD6zOlk3PSEQvF2= M{PofHNCVkeURWK=
CP67-MEL NWDKTZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTjTWM2OD16LkWzNlYh|ryP NYDvPHRsW0GQR2LFVi=>
KALS-1 M4Xp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfoTWM2OD16LkizPFUyKM7:TR?= NI\KWWdUSU6JUlXS
NCI-H1770 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7wTWM2OD16LkmwNlY2KM7:TR?= M1nSZXNCVkeURWK=
8-MG-BA Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PjUWlEPTB;OT6zNlg1PCEQvF2= NWj1R|JzW0GQR2LFVi=>
KY821 NHrNOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTlwN{e0PFQh|ryP NGnKWWVUSU6JUlXS
SNB75 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFyLkC3OkDPxE1? Mlm0V2FPT1KHUh?=
NCCIT M3S2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfte5pKSzVyPUGxMlA2QDJizszN M4PGU3NCVkeURWK=
SJSA-1 M2ruO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu4TmpKSzVyPUGxMlI5QTFizszN M{n1bnNCVkeURWK=
LB373-MEL-D MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjNcldKSzVyPUGxMlM5OjdizszN MmPYV2FPT1KHUh?=
TALL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD6TWM2OD1zMT60NFU5KM7:TR?= M{K1XnNCVkeURWK=
NB69 NGnpWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nWc2lEPTB;MUGuO|cxPSEQvF2= NX3kSXZmW0GQR2LFVi=>
NCI-H1355 NXXaT4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFzLkm0NlYh|ryP NFnkfZZUSU6JUlXS
DMS-153 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4SGlEPTB;MUKuNFQzPiEQvF2= MnH6V2FPT1KHUh?=
OPM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrV[ZNKSzVyPUGyMlE2QTZizszN MnjYV2FPT1KHUh?=
NB1 NV;hTXA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF{LkK5JO69VQ>? NHnFXJJUSU6JUlXS
A3-KAW MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjwTWM2OD1zMj6zNlM3KM7:TR?= NUXlSJZpW0GQR2LFVi=>
NCI-H1882 M1\4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPrVJY3UUN3ME2xNk41ODZ4IN88US=> MYrTRW5IWkWU
KG-1 NHXD[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiwV|JKSzVyPUGyMlY2PDVizszN NEm3RohUSU6JUlXS
LC4-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4WJZKSzVyPUGyMlc4ODZizszN MWPTRW5IWkWU
HCE-T NGfvbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSTmZKSzVyPUGzMlAxPDlizszN MlrQV2FPT1KHUh?=
NEC8 M1X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfUflBKSzVyPUGzMlExOzhizszN M4DBbHNCVkeURWK=
IST-MEL1 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LQOmlEPTB;MUOuOVc5QCEQvF2= MlG0V2FPT1KHUh?=
EW-3 M13Vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[xTWM2OD1zMz63OFAzKM7:TR?= NXrxN2Z5W0GQR2LFVi=>
CTB-1 M4nsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF2LkCzNlkh|ryP NH3wPWdUSU6JUlXS
LS-123 M4HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF2LkG1PFgh|ryP MUjTRW5IWkWU
NCI-H1417 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7zT4liUUN3ME2xOE4{ODV{IN88US=> NVvvNHV5W0GQR2LFVi=>
MZ7-mel NEHHbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;3fmlEPTB;MUSuOFQ{OyEQvF2= NEPaNI9USU6JUlXS
JiyoyeP-2003 NVnYbod3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3yTWM2OD1zNT62N|I3KM7:TR?= MmWzV2FPT1KHUh?=
ES6 NETXZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF4LkKzOlEh|ryP MlzFV2FPT1KHUh?=
HH NIDGbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\ZTWM2OD1zNz6xPVY{KM7:TR?= NWfZfXAzW0GQR2LFVi=>
SF539 NWTyXWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvYTWM2OD1zNz65PVIzKM7:TR?= M{HYWnNCVkeURWK=
Calu-6 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\xPWlEPTB;MUmuNlM6KM7:TR?= MWDTRW5IWkWU
SK-MM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETFSppKSzVyPUG5MlU2PSEQvF2= MVTTRW5IWkWU
IST-MES1 NFfvVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PtUGlEPTB;MUmuOlY3OyEQvF2= MkDkV2FPT1KHUh?=
GI-ME-N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXrfIExUUN3ME2xPU45OjJ5IN88US=> MofiV2FPT1KHUh?=
CAL-148 M4T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Lnc2lEPTB;MkCuPVk{PCEQvF2= MmPGV2FPT1KHUh?=
EVSA-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPYOlhKSzVyPUKxMlE1QTlizszN NH3tNGJUSU6JUlXS
LP-1 M{nUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJzLkO0N|Ih|ryP Mn6zV2FPT1KHUh?=
BOKU MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq1Z2s1UUN3ME2yNU41PTN|IN88US=> M3f5WHNCVkeURWK=
KLE Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfnfHhKSzVyPUKyMlE6ODNizszN MV3TRW5IWkWU
LB831-BLC M3;EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\jSppKSzVyPUK1MlE2OjZizszN NF22VXBUSU6JUlXS
NCI-H889 M4nB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ3LkG5N|Eh|ryP MYnTRW5IWkWU
REH NVfDbm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PaeWlEPTB;MkWuOFY4OSEQvF2= NHfjfZlUSU6JUlXS
KP-N-RT-BM-1 NUjpc2x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGyTWM2OD1{NT60O|UzKM7:TR?= NYm3RWVyW0GQR2LFVi=>
MPP-89 NGjBXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf5TWM2OD1{NT61N|E1KM7:TR?= M3f6UHNCVkeURWK=
no-11 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLBTWM2OD1{NT63OFch|ryP NInHXWZUSU6JUlXS
NCI-H748 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TvcGlEPTB;MkWuO|YzPyEQvF2= M4PlS3NCVkeURWK=
LB2518-MEL M17nZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33HU2lEPTB;MkeuNVc4OyEQvF2= NGnvWVBUSU6JUlXS
TGBC1TKB NUfNWXBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmcGlpUUN3ME2yO{42PTh3IN88US=> MoOzV2FPT1KHUh?=
MHH-PREB-1 M3PsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnnWnBiUUN3ME2yPE4xPzN2IN88US=> MX3TRW5IWkWU
MZ2-MEL NH\6V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\NNG9KSzVyPUK4MlYyPDNizszN MmXtV2FPT1KHUh?=
U-266 M2fXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDqbHpKSzVyPUK4MlY{PjZizszN MoWzV2FPT1KHUh?=
SNU-C1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TUO2lEPTB;MkiuPVQ{KM7:TR?= NVjJSYhLW0GQR2LFVi=>
SW962 NH;kb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNyLkK3OFch|ryP Mo\FV2FPT1KHUh?=
Raji M3XrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17SeGlEPTB;M{CuOVU6OiEQvF2= MWDTRW5IWkWU
KNS-42 M3;KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofzTWM2OD1|MD64PVU3KM7:TR?= Mn64V2FPT1KHUh?=
LB996-RCC M13leWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;jdWlEPTB;M{GuNVcxOiEQvF2= MXzTRW5IWkWU
CHP-126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfkTWM2OD1|MT6xPVg1KM7:TR?= M3jUTnNCVkeURWK=
RXF393 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K3RmlEPTB;M{KuOFk4KM7:TR?= M4rKOnNCVkeURWK=
COLO-684 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTDTWM2OD1|Mj62OFM5KM7:TR?= M3jkO3NCVkeURWK=
A704 NF3YeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnjboYxUUN3ME2zN{42PTN6IN88US=> NVPBToZwW0GQR2LFVi=>
A253 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjhbXZZUUN3ME2zN{42QDV{IN88US=> NIjuc2JUSU6JUlXS
KNS-81-FD M4PCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDaTWM2OD1|ND61OFU3KM7:TR?= NF7HVo9USU6JUlXS
TE-441-T M1HFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:zNmlEPTB;M{SuOlM4OSEQvF2= NFywWlhUSU6JUlXS
HCC2157 NGHwSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN3LkS2NVkh|ryP MXPTRW5IWkWU
ES3 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5TWM2OD1|Nj62O|Uh|ryP NFLac|JUSU6JUlXS
NCI-H1155 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN5LkixOUDPxE1? MXvTRW5IWkWU
SNU-C2B MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHuTWM2OD1|OD6xOlU1KM7:TR?= MkTmV2FPT1KHUh?=
JAR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCyTWM2OD1|OD6yOFQ6KM7:TR?= MnuyV2FPT1KHUh?=
GDM-1 NHnKXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrNepJKSzVyPUO4MlkyOTZizszN MoDqV2FPT1KHUh?=
KU812 M1L5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\MOGlKSzVyPUSxMlUxPyEQvF2= NHLaVndUSU6JUlXS
BC-1 NGjBUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTR{Lk[3N|Eh|ryP MUTTRW5IWkWU
GI-1 NX\SVY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDP[IxKSzVyPUSyMlkyQTJizszN MUPTRW5IWkWU
NCI-H1694 M2nmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorHTWM2OD12ND65OFczKM7:TR?= MVjTRW5IWkWU
DG-75 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMSGlEPTB;NEWuNVU4PyEQvF2= NVfrS4p[W0GQR2LFVi=>
COR-L88 NI[wS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrzbWVXUUN3ME20OU4zPzd6IN88US=> NYLSfY9tW0GQR2LFVi=>
LS-513 NHWwN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTONYZFUUN3ME20OU46OTV4IN88US=> NI\BbFNUSU6JUlXS
HD-MY-Z NEX2fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe5TWM2OD12Nj60OlEzKM7:TR?= MYDTRW5IWkWU
L-363 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LKPGlEPTB;NE[uPFgyKM7:TR?= M372V3NCVkeURWK=
TE-6 NVHiNmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP4PIJUUUN3ME20PE41PDZizszN Ml7qV2FPT1KHUh?=
NCI-H345 M1jEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXRTWM2OD12OD60Olgh|ryP M1r2UHNCVkeURWK=
TE-5 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6VY5KSzVyPUS5MlcyOThizszN M1;uVXNCVkeURWK=

... Click to View More Cell Line Experimental Data

In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]

Protocol

Kinase Assay:

[3]

+ Expand

Kinase inhibition assays:

The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research:

[2]

+ Expand
  • Cell lines: CAL-62 cells
  • Concentrations: 5-500 nM
  • Incubation Time: 4 days
  • Method:

    The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells
  • Formulation: 50% PEG300 in 50 mM phosphate buffer
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.59
Formula

C23H28N8OS

CAS No. 639089-54-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00500006 Terminated Chronic Myelogenous Leukemia|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Merck Sharp & Dohme Corp. October 2007 Phase 1
NCT00405054 Terminated Leukemia Merck Sharp & Dohme Corp. December 2006 Phase 2
NCT00290550 Terminated Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme Corp. June 2006 Phase 2
NCT00111683 Completed Chronic Myelogenous Leukemia in Blast Crisis|Lymphocytic Leukemia, B Cell, Acute|Myelodysplastic Syndromes|Myelogenous Leukemia, Chronic Merck Sharp & Dohme Corp. June 2005 Phase 1
NCT02532868 Terminated Cancer Merck Sharp & Dohme Corp. May 2005 Phase 1
NCT00099346 Terminated Colorectal Cancer|Advanced Solid Tumors Merck Sharp & Dohme Corp. January 2005 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) supplier | purchase Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) cost | Tozasertib (VX-680, MK-0457) manufacturer | order Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID